Illumina (ILMN) concentration risks

The company's concentration profile is defined by an overwhelming structural dependence on a single product category, compounded by a supply-side dependency and a geographic exposure to Greater China. Sequencing revenue comprised 92% of total revenue in 2025 — a high-share structural concentration that makes the company's entire financial profile contingent on the commercial trajectory of its sequencing platform. This is a deliberate strategic focus rather than an accidental accumulation of exposure, but it means that pricing pressure, competitive displacement, or technological obsolescence in sequencing would affect the vast majority of the revenue base simultaneously. On the supply side, certain raw materials and components are obtained from single-source suppliers — a high-share dependency that is cross-cutting across the manufacturing base. A disruption to any critical single-sourced input could constrain instrument or consumable production and limit the company's ability to fulfill customer orders, regardless of underlying demand strength. The geographic exposure to Greater China — which includes China, Taiwan, and Hong Kong — generated revenue of $243 million in 2025, a low-share contribution at the disclosed level. That exposure introduces geopolitical and regulatory risk given the sensitivity around genomics data and technology transfer in the region, though the absolute revenue contribution is limited relative to the total business. On balance, the sequencing product concentration is the dominant item in the profile; the sole-source supply dependency and China exposure are secondary but real risk layers.

For the engine’s reasoning on ILMN’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.